Nuvelution Pharma, Inc.
United States of America
Thomas Dyrberg, MD joined Novo A/S in 2000. He is a member of the Boards of Directors of Delenex Therapeutics AG, Ophthotech Corporation, PanOptica Inc., and Veloxis Pharmaceuticals A/S. Dr. Dyrberg held research positions at the Hagedorn Research Institute, Denmark, and at the Scripps Research Institute, La Jolla, US. In 1990, he joined Novo Nordisk A/S, initially working in Health Care Discovery on various aspects of diabetes immunology and pathogenesis, and from 1996 in Health Care Clinical Drug Development. Dr. Dyrberg obtained an MD degree from the University of Copenhagen in 1981 and a DMSc degree, also from the University of Copenhagen in 1986.